Q2009 HCPCS code: Injection, fosphenytoin, 50 mg phenytoin equivalent
Q2009 is the HCPCS Level II code for injection, fosphenytoin, 50 mg phenytoin equivalent. Its Medicare coverage code is D (Special coverage instructions apply): Medicare covers it when its national or local coverage criteria are met. The NCCI unit limit is 100 per day on outpatient hospital claims.
Code details
| Field | Value |
|---|---|
| Section | Q codes — Temporary codes |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2000-07-01 |
| Last action effective | 2020-01-01 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 100 | Clinical: Data |
| practitioner claims | 100 | Clinical: CMS Workgroup |
What changed for Q2009
- 2000-07-01: Q2009 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code Q2009?
Q2009 is the HCPCS Level II code for injection, fosphenytoin, 50 mg phenytoin equivalent. Short descriptor: "Fosphenytoin inj pe".
Does Medicare cover Q2009?
Coverage code D — Special coverage instructions apply. Medicare covers it when its national or local coverage criteria are met.
How many units of Q2009 can be billed per day?
100 on outpatient hospital claims; 100 on practitioner claims (NCCI medically unlikely edits).
Related Q20 codes
- Q2004 — Irrigation solution for treatment of bladder calculi, for example renacidin, per 500 ml
- Q2017 — Injection, teniposide, 50 mg
- Q2026 — Injection, radiesse, 0.1 ml
- Q2028 — Injection, sculptra, 0.5 mg
- Q2034 — Influenza virus vaccine, split virus, for intramuscular use (agriflu)
- Q2035 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)
- Q2036 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)
- Q2037 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)
- Q2038 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)
- Q2039 — Influenza virus vaccine, not otherwise specified
- Q2040 — Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
- Q2041 — Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under Q2009
- Watch Q2009 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q2009
Sources: CMS HCPCS Level II release October 2025; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.